ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®
Portfolio Pulse from
ANI Pharmaceuticals has completed a buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC for ILUVIEN and YUTIQ, paying $17.25 million. This eliminates future royalty payments, effective January 1, 2025.
March 18, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals has eliminated its 3.125% royalty obligation on ILUVIEN and YUTIQ by paying $17.25 million to SWK Funding LLC. This move is expected to improve future net revenues as no further royalties will be due from January 1, 2025.
By buying out the royalty obligation, ANI Pharmaceuticals will retain more of its net revenues from ILUVIEN and YUTIQ, potentially increasing profitability. The use of cash on hand for this transaction indicates financial stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100